Combined effect of liposomal and conventional amphotericin B in a mouse model of systemic infection with Candida albicans.
Amphotericin B may be employed as a potentially toxic deoxycholate complex or incorporated in liposomes and other particles which have an altered tissue distribution. A combination of both preparations could help to overcome the drawbacks of the individual preparations. We have employed a mouse model of systemic infection with Candida albicans to investigate whether this assumption was essentially true. We found that the combination of low dosages of both preparations (0.5 mg/kg of body weight/day of conventional and 0.5 mg kg of body weight/day liposomal amphotericin B) was more efficient than a similar dosage of conventional amphotericin B (1 mg/kg of body weight/day) in the liver and similar or higher dosages of liposomal amphotericin B (1 or 5 mg/kg of body weight/day) in the kidneys.
Institut für Medizinische Mikrobiologie und Hygiene, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, 68167 Mannheim, Germany.
M
M
Kretschmar
T
T
Bertsch
T
T
Nichterlein
D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004337:Drug Carriers; D005260:Female; D016469:Fungemia / Q000188:drug therapy*; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D011336:Probability; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B